News and Announcements
MedAdvisor Signs Strategic Agreement with Arrow Pharmaceuticals
- Published June 01, 2016 2:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st June 2016, ASX Announcement
Highlights:
- MedAdvisor has sign a strategic agreement with Arrow Pharmaceuticals, one of Australia’s largest generic pharmaceutical manufacturers
- Arrows Pharmaceuticals’ 35 plus strong national sales teams to promote the MedAdvisor platform to its extensive first-line customer base of over 1,100 pharmacies from June 2016
- Strong platform validation with MedAdvisor now partnered with Australia’s two largest generic companies: Apotex and Arrow Pharmaceuticals
- Aligns with MedAdvisor’s strategy to substantially increase its referrer and patient customer base to drive revenue and growth
MedAdvisor Limied (ASX:MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a binding strategic agreement with Arrow Pharmaceuticals, Australia’s second largetst generic pharmaceutical manufactures, following the announcement of its Memorandum of Understanding in March 2016.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
